MAGEA3 and neoplasm: After the challenge with TC1-MAGE-A3 tumor cells, all PBS-immunized mice developed a tumor and were sacrificed, whereas 52 of 60 recMAGE-A3+AS15-immunized mice rejected the tumor and remained tumor-free for at least two months (Figure 3A).